Global Rare Disease Drug Market Analysis and Forecast, 2023-2028

The global rare disease drug market was estimated at a market value of US$ 192 billion in 2022 and is expected to grow at a significant CAGR of over 11.8% over the forecast period of 2023-2028.

Market Scope and Report Overview

According to a deep-dive market assessment by RationalStat, the global rare disease drug market has been analyzed on the basis of market segments, including type, application, and geography/regions (incl. North America, Latin America, Western Europe, Eastern Europe, Middle East & Africa, and Asia Pacific). The report also offers global and regional market sizing for the historical period of 2019-2022 and the forecast period of 2023-2028.

Market intelligence for the global rare disease drug market covers market sizes on the basis of market value (US$/EUR Million) and volume ('000 units/tons/liters) by various products/services/equipment, demand assessment across the key regions, customer sentiments, price points, cost structures, margin analysis across the value chain, financial assessments, historical and forecast data, key developments across the industry, import-export data, trade overview, components market by leading companies, etc.

In addition, the long-term sector and products/services 10-year outlook and its implications on the global rare disease drug market. It also includes the industry's current state - Production Levels, Capacity Utilization, Tech quotient, etc. Key information will be manufacturing capacity by country, installed base, import volumes, market size, key players, market size, dynamics, market data, insights, etc.

Period Covered include data for 2023-2028 along with year-wise demand estimations

The rare disease drug market report analyzes the market on the basis of global economic situations, regional geopolitics, import-export scenarios, trade duties, market developments, organic and inorganic strategies, mergers and acquisitions, product launches, government policies, new capacity addition, technological advancements, R&D investments, and new market entry, replacement rates, penetration rates, installed base/fleet size, global and regional production capacity, among others.

RationalStat offers market analysis and consulting studies on the basis of dedicated and robust desk/secondary research supported by a strong in-house data repository. In addition, the research leverages data based on the real-time insights gathered from primary interviews. Market estimations and insights are based on primary research (covering more than 240 entities) and secondary research by leveraging international benchmarking.

The global rare disease drug market report also covers value chain and supply chain analysis that provides in-depth information about the value chain margins and the role of various stakeholders across the value chain. Market dynamics provided in the market study include market drivers, restraints/ challenges, trends, and their impact on the market throughout the analysis period.

In the competition analysis section, the global rare disease drug market provides a detailed competition benchmarking analysis based on the market share of the leading companies/brands/producers/ suppliers, a market structure overview with detailed company profiles of more than 25 players with their financials, product/service offerings, major developments, business models, etc. This enables, clients and report buyers to make strong, precise, and timely decisions.

Explore more about this report - Request for Sample and Scope of the Study
https://store.rationalstat.com/store/global-rare-disease-drug-market/#tab-ux_global_tab

Macroeconomic Scenario and the Impact of COVID-19 on Regional Economic Sentiment

In the latest RationalStat analysis, geopolitical conflicts and inflation are the cited economic risks, while concerns about the volatility across energy sectors prevail in Europe and other parts of the world. Some of the potential risks to the economic growth in the leading regions, including Asia Pacific, Europe, North America, the Middle East & Africa, and other developing regions, are inflation, volatile energy prices, supply chain disruptions, geopolitical instability, labor shortages, rising interest rates, and COVID-19 pandemic.

The global economy experienced heavy headwinds, throughout 2019-2021, as some countries witnessed subdued growth, while other countries continued to grapple with economic slowdowns. The COVID-19 pandemic has levied undue pressure across the majority of industries globally and has caused a major economic crisis in the US, India, Italy, the UK, Germany, India, Japan, South Korea, the UK, and many others. Besides, the exit of the UK from the European Union earlier in 2020 and the Russo-Ukraine war in 2022 exacerbated the ever-heightened global uncertainty.

In addition to this, the global economic growth slowed in 2022 to 3.3%, weaker than expected at the end of 2021, mainly weighed down by Russia's war in Ukraine and the associated cost-of-living crisis in many countries. However, improvement in economic activities during the forecast period is expected. Growth is projected to remain at lower rates in 2023 and 2024, at 2.6% and 2.9% respectively.

Competition Analysis and Market Structure

Some of the prominent players that contribute significantly to the global rare disease drug market growth include AbbVie Inc., AstraZeneca, Amgen Inc., Baxter, Bayer AG, Biomarin Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Co. Ltd, Eli Lilly and Company, Novartis AG, and among others.

RationalStat has segmented the global rare disease drug market based on type, application, and region
• Global Rare Disease Drug Market Value (US$ Million), Volume ('000 units/tons), and Market Share (2023-2028) Analysis by Type
o Biologics
o Non-biologics
• Global Rare Disease Drug Market Value (US$ Million), Volume ('000 units/tons), and Market Share (2023-2028) Analysis by Application
o Genetic Diseases
o Neurological Diseases
o Oncology
o Infectious Diseases
o Cardiovascular Diseases
o Others
• Global Rare Disease Drug Market Value (US$ Million), Volume ('000 units/tons), and Market Share (2023-2028) Analysis by Region
o North America Rare Disease Drug Market
 US
 Canada
o Latin America Rare Disease Drug Market
 Brazil
 Mexico
 Rest of Latin America
o Western Europe Rare Disease Drug Market
 Germany
 UK
 France
 Spain
 Italy
 Benelux
 Nordic
 Rest of Western Europe
o Eastern Europe Rare Disease Drug Market
 Russia
 Poland
 Hungary
 Other CIS Countries
 Rest of Eastern Europe
o Asia Pacific Rare Disease Drug Market
 China
 Japan
 India
 South Korea
 Australia
 ASEAN
• Indonesia
• Thailand
• Philippines
• Vietnam
• Malaysia
• Rest of ASEAN
 Rest of Asia Pacific
o Middle East & Africa Rare Disease Drug Market
 GCC
• Saudi Arabia (KSA)
• United Arab Emirates (UAE)
• Rest of the GCC
 South Africa
 Nigeria
 Turkey
 Rest of the Middle East & Africa

• Leading Companies and Market Players
o AbbVie Inc.
o AstraZeneca
o Amgen Inc.
o Baxter
o Bayer AG
o Biomarin Pharmaceuticals
o Bristol-Myers Squibb Company
o Eisai Co. Ltd
o Eli Lilly and Company
o Novartis AG.

For more information about this report https://store.rationalstat.com/store/global-rare-disease-drug-market/

Key Questions Answered in the Rare Disease Drug Report:

• What will be the market value of the global rare disease drug market by 2028?
• What is the market size of the global rare disease drug market?
• What are the market drivers of the global rare disease drug market?
• What are the key trends in the global rare disease drug market?
• Which is the leading region in the global rare disease drug market?
• What are the major companies operating in the global rare disease drug market?
• What are the market shares by key segments in the global rare disease drug market?

Kimberly Shaw,
Content and Press Manager
RationalStat LLC
sales@rationalstat.com
Phone: +1 302 803 5429

RationalStat is an end-to-end global market intelligence and consulting company that provides comprehensive market research reports, customized strategy, and consulting studies. The company has sales offices in India, Mexico, and the US to support global and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.
RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client's needs. Additional services offered by the company include consumer research, country reports, risk reports, valuations and advisory, financial research, due diligence, procurement and supply chain research, data analytics, and analytical dashboards.

This release was published on openPR.